New Method of SNP Typing in Aging Related Disorders

衰老相关疾病的 SNP 分型新方法

• 批准号: 6622283
• 负责人: David Schultz
• 金额: $ 36.72万
• 依托单位: SEASHELL TECHNOLOGY, LLC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6622283
• 关键词: Alzheimer's disease; aging; biotechnology; breast neoplasms; cardiovascular disorder; gene mutation; genetic screening; genotype; method development; microarray technology; nucleic acid hybridization; reporter genes; single nucleotide polymorphism

DESCRIPTION (provided by applicant): The objectives of this proposal is to commercialize a novel assay we have developed in our phase I research for the detection of genetic variants (SNPs) that may be linked to aging related disorders such as Alzheimer's disease, breast cancer and cardiovascular disease. The specific aims are the further development of this economical and ultra-sensitive platform for identification of single nucleotide polymorphisms (SNPs). This new approach will eliminate the typical requirement for a PCR amplification step in SNP assays, and therefore will be ideally suited for ultra-high throughput screening of large populations. The assay is based on the use of an oligonucleotide ligation assay (OLA), a DNA microarray, and our novel reporter label (PRP) that allows for ultrasensitive detection of DNA. We expect that the completion of our SBIR program will result in the commercialization of SNP identification using kits, protocols, and reagents for population screening and pharmacogenomics for sale to both the research and clinical biomedical communities. PROPOSED COMMERCIAL APPLICATION: The sale of kits and reagents that will become the preferred methodology for the screening of human populations for SNPs associated with specific age related diseases, such as Alzheimer's, breast cancer, and cardiovascular deterioration. The design of inexpensive user-friendly instrumentation suitable for individual medical practioners, clinical screening laboratories, and research facilities.

描述（由申请人提供）：该提案的目标是 将我们在第一阶段研究中开发的一种新测定方法商业化 检测可能与衰老相关的遗传变异（SNP） 阿尔茨海默病、乳腺癌和心血管疾病等疾病 疾病。具体目标是进一步发展这一经济和 用于鉴定单核苷酸多态性的超灵敏平台 （SNP）。这种新方法将消除 PCR 的典型要求 SNP 检测中的扩增步骤，因此非常适合 对大量人群进行超高通量筛查。 该测定基于寡核苷酸连接测定 (OLA) 的使用，这是一种 DNA 微阵列，以及我们的新颖报告标签 (PRP)，可实现超灵敏 DNA检测。 我们预计 SBIR 计划的完成将导致 使用试剂盒、方案和试剂进行 SNP 鉴定的商业化 人群筛查和药物基因组学出售给研究和 临床生物医学界。 拟议的商业应用： 销售的试剂盒和试剂将成为筛查人群中与特定年龄相关疾病（如阿尔茨海默病、乳腺癌和心血管恶化）相关的 SNP 的首选方法。 设计廉价、用户友好的仪器，适用于个体医疗从业者、临床筛查实验室和研究设施。